Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long-term Balancing Act: Incentives and FOBs Pathway

This article was originally published in RPM Report

Executive Summary

As Congress finishes its work on a pathway for follow-on biologics, a number of key decisions affecting incentives for copies and innovative products remain. No matter how the new legislation turns out, a number of issues will remain to be worked out in practice and will dominate investment and drug development policy for decades to come.

You may also be interested in...



In Brave New World of Follow-On Biologics, Can't We Do Better Than 1984?

Congress has moved into the final horse-trading phase of policy development regarding incentives for innovators and biosimilar product developers. The main question on Capitol Hill is what compromise can generate enough support to survive the political process. Jeffrey MOe, a Duke business school professor with experience developing incentives for drug development policy, suggest Congress should reflect before forging its political decision.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel